Factors associated with abnormal cardio-ankle vascular index in patients with type 2 diabetes and prediabetes

Aim: The purpose of this study was to examine the phenotypic and genetic characteristics of patients with type 2 diabetes mellitus (T2DM) with different responses to treatment with metformin (MF) in the Novosibirsk region. Materials and methods: We examined 460 patients with T2DM in the Novosibirsk...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Aleksei N. Sumin, Natalya A. Bezdenezhnykh, Natalya V. Fedorova, Anna V. Shcheglova, Elena V. Indukaeva, Galina V. Artamonova
Formato: article
Lenguaje:EN
RU
Publicado: Endocrinology Research Centre 2016
Materias:
Acceso en línea:https://doaj.org/article/68498cecb1174a539cf5c5e649f813f3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:68498cecb1174a539cf5c5e649f813f3
record_format dspace
spelling oai:doaj.org-article:68498cecb1174a539cf5c5e649f813f32021-11-14T09:00:20ZFactors associated with abnormal cardio-ankle vascular index in patients with type 2 diabetes and prediabetes2072-03512072-037810.14341/DM2004112-15https://doaj.org/article/68498cecb1174a539cf5c5e649f813f32016-05-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/7711https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aim: The purpose of this study was to examine the phenotypic and genetic characteristics of patients with type 2 diabetes mellitus (T2DM) with different responses to treatment with metformin (MF) in the Novosibirsk region. Materials and methods: We examined 460 patients with T2DM in the Novosibirsk region. Patients were divided into groups according to their HbA1c level: patients who achieved the target HbA1c level during MF therapy (n = 209) and those who did not reach the target HbA1c level (n=251). Genotyping of ATM (rs11212617) was performed using polymerase chain reaction by TaqMan. Results: Patients who achieved the target HbA1c level during MF treatment (good response) were older (61. 1±9. 1 years vs. 57. 4±8. 4 years, p=0. 001), had later onset of diabetes (54. 6 ± 10. 1 years vs. 49. 2±8. 5 years, p = 0. 0001) and shorter duration of diabetes (6. 5±5. 9 years vs. 8. 2±6. 1 years, p=0. 03) compared with those who did not achieve the target HbA1c level. There was no statistically significant association between ATM rs11212617 and achieving the target HbA1c level among all patients [odds ratio (OR)=0. 94, 95% confidence interval = (0. 73–1. 23), p=0. 67] or those with MF monotherapy [OR=0. 90, (0. 65–1. 25), p=0. 54] or combination therapy [OR=1. 02, (0. 72–1. 43), p=0. 92]. There was an effect of age on response to MF therapy in all three groups (all patients: p=0. 001, MF monotherapy group: p=0. 04, combination therapy group: p=0. 0009). In the MF monotherapy group, low dose MF was associated with a good response (p=0. 03), and in the combination therapy group, males were more likely to have a good response (p=0. 003). Patients with genotype C/C or A/C for ATM (rs11212617) compared with those with genotype A/A were more likely to have high levels of triglycerides [2. 33 (1. 52–4. 2) mmol/l, 2. 09 (1. 35–3. 0) mmol/l and 1. 99 (1. 49–3. 21) mmol/l, respectively, p=0. 001], coronary heart disease (CHD) (13. 4%, 13. 4% and 9. 6%, respectively, p=0. 009) and myocardial infarction (7. 8%, 3. 2% and 4. 0%, respectively, p=0. 001). Conclusion: Patients with T2DM who had a good response to MF therapy were older, more likely to be male and had a later onset of T2DM. Genotype C/C for ATM rs11212617 was associated with high triglycerides, CHD and myocardial infarction. ATM rs11212617 was not associated with response to MF therapy in the Novosibirsk region.Aleksei N. SuminNatalya A. BezdenezhnykhNatalya V. FedorovaAnna V. ShcheglovaElena V. IndukaevaGalina V. ArtamonovaEndocrinology Research Centrearticletype 2 diabetes mellitusmetforminatm (rs11212617)Nutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 19, Iss 2, Pp 132-140 (2016)
institution DOAJ
collection DOAJ
language EN
RU
topic type 2 diabetes mellitus
metformin
atm (rs11212617)
Nutritional diseases. Deficiency diseases
RC620-627
spellingShingle type 2 diabetes mellitus
metformin
atm (rs11212617)
Nutritional diseases. Deficiency diseases
RC620-627
Aleksei N. Sumin
Natalya A. Bezdenezhnykh
Natalya V. Fedorova
Anna V. Shcheglova
Elena V. Indukaeva
Galina V. Artamonova
Factors associated with abnormal cardio-ankle vascular index in patients with type 2 diabetes and prediabetes
description Aim: The purpose of this study was to examine the phenotypic and genetic characteristics of patients with type 2 diabetes mellitus (T2DM) with different responses to treatment with metformin (MF) in the Novosibirsk region. Materials and methods: We examined 460 patients with T2DM in the Novosibirsk region. Patients were divided into groups according to their HbA1c level: patients who achieved the target HbA1c level during MF therapy (n = 209) and those who did not reach the target HbA1c level (n=251). Genotyping of ATM (rs11212617) was performed using polymerase chain reaction by TaqMan. Results: Patients who achieved the target HbA1c level during MF treatment (good response) were older (61. 1±9. 1 years vs. 57. 4±8. 4 years, p=0. 001), had later onset of diabetes (54. 6 ± 10. 1 years vs. 49. 2±8. 5 years, p = 0. 0001) and shorter duration of diabetes (6. 5±5. 9 years vs. 8. 2±6. 1 years, p=0. 03) compared with those who did not achieve the target HbA1c level. There was no statistically significant association between ATM rs11212617 and achieving the target HbA1c level among all patients [odds ratio (OR)=0. 94, 95% confidence interval = (0. 73–1. 23), p=0. 67] or those with MF monotherapy [OR=0. 90, (0. 65–1. 25), p=0. 54] or combination therapy [OR=1. 02, (0. 72–1. 43), p=0. 92]. There was an effect of age on response to MF therapy in all three groups (all patients: p=0. 001, MF monotherapy group: p=0. 04, combination therapy group: p=0. 0009). In the MF monotherapy group, low dose MF was associated with a good response (p=0. 03), and in the combination therapy group, males were more likely to have a good response (p=0. 003). Patients with genotype C/C or A/C for ATM (rs11212617) compared with those with genotype A/A were more likely to have high levels of triglycerides [2. 33 (1. 52–4. 2) mmol/l, 2. 09 (1. 35–3. 0) mmol/l and 1. 99 (1. 49–3. 21) mmol/l, respectively, p=0. 001], coronary heart disease (CHD) (13. 4%, 13. 4% and 9. 6%, respectively, p=0. 009) and myocardial infarction (7. 8%, 3. 2% and 4. 0%, respectively, p=0. 001). Conclusion: Patients with T2DM who had a good response to MF therapy were older, more likely to be male and had a later onset of T2DM. Genotype C/C for ATM rs11212617 was associated with high triglycerides, CHD and myocardial infarction. ATM rs11212617 was not associated with response to MF therapy in the Novosibirsk region.
format article
author Aleksei N. Sumin
Natalya A. Bezdenezhnykh
Natalya V. Fedorova
Anna V. Shcheglova
Elena V. Indukaeva
Galina V. Artamonova
author_facet Aleksei N. Sumin
Natalya A. Bezdenezhnykh
Natalya V. Fedorova
Anna V. Shcheglova
Elena V. Indukaeva
Galina V. Artamonova
author_sort Aleksei N. Sumin
title Factors associated with abnormal cardio-ankle vascular index in patients with type 2 diabetes and prediabetes
title_short Factors associated with abnormal cardio-ankle vascular index in patients with type 2 diabetes and prediabetes
title_full Factors associated with abnormal cardio-ankle vascular index in patients with type 2 diabetes and prediabetes
title_fullStr Factors associated with abnormal cardio-ankle vascular index in patients with type 2 diabetes and prediabetes
title_full_unstemmed Factors associated with abnormal cardio-ankle vascular index in patients with type 2 diabetes and prediabetes
title_sort factors associated with abnormal cardio-ankle vascular index in patients with type 2 diabetes and prediabetes
publisher Endocrinology Research Centre
publishDate 2016
url https://doaj.org/article/68498cecb1174a539cf5c5e649f813f3
work_keys_str_mv AT alekseinsumin factorsassociatedwithabnormalcardioanklevascularindexinpatientswithtype2diabetesandprediabetes
AT natalyaabezdenezhnykh factorsassociatedwithabnormalcardioanklevascularindexinpatientswithtype2diabetesandprediabetes
AT natalyavfedorova factorsassociatedwithabnormalcardioanklevascularindexinpatientswithtype2diabetesandprediabetes
AT annavshcheglova factorsassociatedwithabnormalcardioanklevascularindexinpatientswithtype2diabetesandprediabetes
AT elenavindukaeva factorsassociatedwithabnormalcardioanklevascularindexinpatientswithtype2diabetesandprediabetes
AT galinavartamonova factorsassociatedwithabnormalcardioanklevascularindexinpatientswithtype2diabetesandprediabetes
_version_ 1718429534291755008